RxDoctor Payments Data

George Alcorn, MD

Internal Medicine · Madison, INNPI 1457341281

Payments from drug & device makers

$3,674in general payments, 2019–2025

Across 86 payments — averaging $42.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$421
  • Novo Nordisk$297
  • Regeneron Healthcare Solutions, Inc.$287
  • Eisai Inc.$122
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$81
  • plus $317 from 8 others

What the payments were for

  • Food & beverage$3,60298%
  • Education$722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,674 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$313,368
Medicare patients
909
Services billed
24,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter622$857,087
OzempicSemaglutide491$559,498
Breztri AerosphereBudesonide/Glycopyr/Formoterol246$330,248
TezspireTezepelumab-Ekko52$227,531
EliquisApixaban241$211,978
MounjaroTirzepatide132$156,755
Breo ElliptaFluticasone/Vilanterol196$154,257
FarxigaDapagliflozin Propanediol127$146,075
RexultiBrexpiprazole81$133,516
Tresiba Flextouch U-200Insulin Degludec100$133,383
Dupixent PenDupilumab30$130,166
Fasenra PenBenralizumab17$106,429
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr91$95,991
Spiriva RespimatTiotropium Bromide72$89,214
Tresiba Flextouch U-100Insulin Degludec101$74,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$421$1,107,336909 claims
AstraZenecaBreztri Aerosphere, Tezspire, Farxiga, Symbicort, Airsupra$2,148$755,838533 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$297$634,753537 claims
Lilly USA, LLCMounjaro$41$156,755132 claims
AbbVieVraylar, Creon, Linzess$69$85,67748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Madison

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →